Literature DB >> 27185796

Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years.

Laurent Bourguignon1, Yoann Cazaubon2, Guillaume Debeurme3, Constance Loue3, Michel Ducher3, Sylvain Goutelle4.   

Abstract

Since the 1950s, vancomycin has remained a reference treatment for severe infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus Vancomycin is a nephrotoxic and ototoxic drug mainly eliminated through the kidneys. It has a large interindividual pharmacokinetic variability, which justifies monitoring its plasma concentrations in patients. This is especially important in patients aged over 80 years, who frequently have renal impairment. However, the pharmacokinetics of vancomycin in this population is very poorly described in the literature. The objective of this work was to propose a model able to predict the pharmacokinetics of vancomycin in very elderly people. First, a population pharmacokinetic model was carried out using the algorithm NPAG (nonparametric adaptive grid) on a database of 70 hospitalized patients aged over 80 years and treated with vancomycin. An external validation then was performed on 41 patients, and the predictive capabilities of the model were assessed. The model had two compartments and six parameters. Body weight and creatinine clearance significantly influenced vancomycin volume of distribution and body clearance, respectively. The means (± standard deviations) of vancomycin volume of distribution and clearance were 36.3 ± 15.2 liter and 2.0 ± 0.9 liter/h, respectively. In the validation group, the bias and precision were -0.75 mg/liter and 8.76 mg/liter for population predictions and -0.39 mg/liter and 2.68 mg/liter for individual predictions. In conclusion, a pharmacokinetic model of vancomycin in a very elderly population has been created and validated for predicting plasma concentrations of vancomycin.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27185796      PMCID: PMC4958150          DOI: 10.1128/AAC.00303-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

Review 1.  Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.

Authors:  A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

2.  Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches.

Authors:  J L Sánchez; A R Dominguez; J R Lane; P O Anderson; E V Capparelli; J M Cornejo-Bravo
Journal:  Int J Clin Pharmacol Ther       Date:  2010-08       Impact factor: 1.366

3.  Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.

Authors:  Lindsey Pritchard; Catherine Baker; James Leggett; Paul Sehdev; Allen Brown; K Bruce Bayley
Journal:  Am J Med       Date:  2010-12       Impact factor: 4.965

Review 4.  Drug therapy in the elderly.

Authors:  Klaus Turnheim
Journal:  Exp Gerontol       Date:  2004 Nov-Dec       Impact factor: 4.032

Review 5.  Pharmacokinetics in older persons.

Authors:  Barry J Cusack
Journal:  Am J Geriatr Pharmacother       Date:  2004-12

6.  Renal elimination of amikacin and the aging process.

Authors:  M Ducher; P Maire; C Cerutti; Y Bourhis; F Foltz; P Sorensen; R Jelliffe; J P Fauvel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation.

Authors:  Hussain Mulla; Suneel Pooboni
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

8.  Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.

Authors:  Roger Jelliffe
Journal:  Am J Nephrol       Date:  2002 Jul-Aug       Impact factor: 3.754

9.  Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.

Authors:  Tatiana Tatarinova; Michael Neely; Jay Bartroff; Michael van Guilder; Walter Yamada; David Bayard; Roger Jelliffe; Robert Leary; Alyona Chubatiuk; Alan Schumitzky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-13       Impact factor: 2.745

Review 10.  Vancomycin therapeutics and monitoring: a contemporary approach.

Authors:  M L Avent; V L Vaska; B A Rogers; A C Cheng; S J van Hal; N E Holmes; B P Howden; D L Paterson
Journal:  Intern Med J       Date:  2013-02       Impact factor: 2.048

View more
  2 in total

1.  Outcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older.

Authors:  Yunchao Wang; Ning Dai; Wei Wei; Chunyan Jiang
Journal:  Clin Interv Aging       Date:  2021-06-01       Impact factor: 4.458

Review 2.  Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application.

Authors:  Katie E Barber; Allison M Bell; Kayla R Stover; Jamie L Wagner
Journal:  Drugs Aging       Date:  2016-12       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.